Comparison of rituximab efficacy in treatment-naïve and refractory inflammatory myopathies: experiences from a tertiary care centre
Authors' conclusion
RTX is effective and safe across the spectrum of IIM. Early use in disease is associated with better outcomes.
Study context
- Population
- Patients with idiopathic inflammatory myopathies (IIM) treated with rituximab (RTX) (including 18 with anti-signal recognition particle myopathy), tertiary care centre55 assessed at 6 months
- Participants
- 60 patients
- Exposure
- RTX in treatment-naïve vs refractory IIM
- Treatment-naïven = 33
- Refractoryn = 27reference
- Outcome
- Treatment response (improved, worsening or stable) based on MMT8 scores, patient and physician global improvement for skin and joint symptoms, and spirometry
- Follow-up
- 6 months
Methodological detailsprospectively maintained database, single-centre (tertiary care centre)
- Prospectively maintained database
- Single-centre (tertiary care centre)
Main finding
As reported in the abstract
Treatment response
P = 0.006*
- Overall response
- 48/55 (87%)
Observational data: associations, not effects.
Further findings
Mean
| Outcome | Treatment-naïve | Refractory | P value |
|---|---|---|---|
| Mean change in MMT8 | 13.41 (SD 7.31) | 8.33 (SD 7.92) | P = 0.017* |
- Stable disease, refractory · 6 months
- 29% · 7
GC dose · before 6 months
- Majority able to reduce dose to <5 mg/day before 6 months
Safety
Major adverse events · median follow-up 24 (IQR 36) months
- No major adverse events reported
Original publication
Comparison of rituximab efficacy in treatment-naïve and refractory inflammatory myopathies: experiences from a tertiary care centre. Rheumatology (Oxford). Published 30 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →